154323-57-6 Categories: , ,
  • # LGM Pharma is a Almotriptan CAS# 154323-57-6 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Almotriptan
  • CAS #: 154323-57-6
  • Mode of Action:

    Almotriptan bonds with high affinity to 5-HT1D, 5-HT1B, and 5-HT1F receptors, and has an absolute bioavailability of approximately 70 percent. Peak plasma levels of Almotriptan occur roughly 1 to 3 hours after administration.

  • Pharmacodynamics:

    The therapeutic efficacy of Almotriptan is thought to be attributed to agonist effects at 5-HT1B/1D receptors.  An activation of these receptors aids in cranial vessel constriction, reduced transmission in the trigeminal pain pathways and an inhibition of neuropeptide releases.

  • Metabolism:

    Almotriptan is metabolized by major pathways monoamine oxidase-mediated oxidative deamination and cytochrome P450-mediated oxidation. Renal excretion of Almotriptan is primary, about 70 percent of the dosage, with roughly 40 percent of an administered dose excreted unchanged in urine.

  • Toxicity:

    Patients with severe renal impairment or who have ischemic heart disease should not be administered Almotriptan. In patients with hepatic impairment the recommended starting dose of Almotriptan is 6.25 milligrams, not exceeding 12.5 milligrams in a 24 hour period. Typical side effects include reports of dizziness, nausea, tiredness and dry mouth.

  • IUPAC: N, N-dimethyl-2- [5-(pyrrolidin-1-ylsulfonylmethyl)- 1H-indol-3-yl]-ethanamine
  • ATC: N02CC05
  • PubChem: 123606
  • DrugBank: DB00918
  • Formula: C17-H25-N3-O2-S
  • Molecular Mass: 335.47
  • Synonyms: 1-(((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)sulfonyl)pyrrolidine, Almotriptan, LAS 31416, UNII-1O4XL5SN61
  • SMILES: c1c(cc2c(c[nH]c2c1)CCN(C)C)CS(N1CCCC1)(=O)=O
  • InChl: 1S/C17H25N3O2S/c1-19(2)10-7-15-12-18-17-6-5-14(11-16(15)17)13-23(21,22)20-8-3-4-9-20/h5-6,11-12,18H,3-4,7-10,13H2,1-2H3
  • General Reference:
    1. Neurol Sci. 2014 May;35 Suppl 1:115-9. doi: 10.1007/s10072-014-1752-2.
    2. Headache: The Journal of Head and Face Pain. Multiple years/issues.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants


  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service